The Biomedical Advanced Research and Development Authority, part of HHS, just announced an award as much as $285 million to Paratek, a publicly-owned Boston-based biopharmaceutical company that focuses on infectious disease research, to develop a new antibiotic for anthrax. But, will pull incentives – rewarding companies for the successful development of new antibiotics – be enough to keep large, private companies in the field of antibiotic research? ACSH advisor Dr. David Shlaes explains.
CDC Follies, part two. No, part three. Well, whatever: our nation s chief repository of biological threats (i.e. bioterror weapons, potentially) resembles the gang that couldn t shoot straight. They keep spreading lethal organisms around.
Attention has recently focused on a study of the genetic fingerprint, or DNA, of microorganisms found on and in NYC subways. Some genetic evidence of bacteria linked to bubonic plague and anthrax was found. Should New Yorkers (or anyone) be concerned about this? No.
Executive Summary In the post-Sept. 11 era of terrorism, the federal government has placed great emphasis on the potential threat posed by smallpox as a biological weapon. This stress on smallpox, however, raises a serious question: Are other, perhaps more serious bioterrorism agents - particularly anthrax - being given the attention they deserve? Anthrax, in many respects, is an ideal bioweapon.